{"status":"success","data":{"title":"Ectopic Pregnancy and Methotrexate","slug":"ectopic-methotrexate","tags":["Methotrexate,"],"collection":["OBGYN"],"content":"<h1 id=\"ectopic-pregnancy-and-methotrexate\">Ectopic Pregnancy and Methotrexate</h1>\n<ul>\n<li>2% of all first-trimester pregnancies and 6% of all pregnancy-related deaths</li>\n<li>18% of patients who present with first-trimester bleeding or abdominal pain in the Emergency Department</li>\n<li><p>Risk factors</p>\n<ul>\n<li>Prior tubal, pelvic, or abdominal surgery</li>\n<li>Genital infections leading to pelvic inflammatory disease</li>\n<li>Prior ectopic pregnancy</li>\n<li>In utero exposure to diethylstilbestrol (DES)</li>\n<li>History of infertility</li>\n<li>Use of assisted reproductive technologies (in vitro fertilization)</li>\n<li>Tobacco use</li>\n</ul>\n</li>\n</ul>\n<h2 id=\"methotrexate-mtx-\">Methotrexate (MTX)</h2>\n<p><strong>Background</strong></p>\n<ul>\n<li>Dihydrofolate reductase inhibitor</li>\n<li>Overall success rate for treating ectopic pregnancy = 71-94%</li>\n<li>Success rate of single-dose MTX for B-hCG &gt; 5,000 mIU/mL = 85.7% </li>\n</ul>\n<p><strong>Side Effects</strong></p>\n<ul>\n<li>Abdominal pain</li>\n<li>Nausea/vomiting</li>\n<li>Stomatitis    </li>\n</ul>\n<h2 id=\"eligibility-contraindications-for-mtx-in-ectopic-pregnancy\">Eligibility / Contraindications for MTX in Ectopic Pregnancy</h2>\n<p><strong>Eligibility Criteria:</strong></p>\n<ul>\n<li>High clinical suspicion or confirmed ectopic pregnancy,</li>\n<li>Hemodynamically stable,</li>\n<li>Unruptured mass,</li>\n<li>Able to comply with close follow-up, <strong>AND</strong></li>\n<li>Normal creatinine, liver transaminases, WBC, hematocrit, and platelet counts </li>\n</ul>\n<p><strong>Contraindications:</strong></p>\n<ul>\n<li>Breastfeeding</li>\n<li>Overt or lab evidence of immunodeficiency</li>\n<li>Alcoholism, alcoholic or chronic liver disease</li>\n<li>Preexisting blood dyscrasias or significant anemia </li>\n<li>Known sensitivity to MTX</li>\n<li>Active pulmonary disease</li>\n<li>Peptic ulcer disease</li>\n<li>Hepatic, renal, or hematologic dysfunction</li>\n<li>Gestational sac &gt; 3.5 cm on U/S (relative contraindication) </li>\n<li>Embryonic cardiac motion on U/S (relative contraindication) </li>\n</ul>\n<h2 id=\"single-dose-regimen\">Single-Dose Regimen</h2>\n<ul>\n<li><span class=\"drug\">Methotrexate</span> 50 mg/m2 IM on Day 1</li>\n</ul>\n<p><strong>Follow up with obstetrician to:</strong></p>\n<ul>\n<li>Measure B-hCG on Days 4 and 7</li>\n<li>Check for 15% B-hCG decrease between days 4 and 7</li>\n<li>Measure B-hCG weekly until non-pregnant level</li>\n<li>If B-hCG dose not decrease by &gt;15% as expected, re-dose 50 mg/m2 IM and repeat B-hCG on days 4 and 7 after 2nd dose. </li>\n</ul>\n<h2 id=\"alternative-regimens\">Alternative Regimens</h2>\n<ul>\n<li><strong>Two-Dose</strong> and <strong>Fixed Multidose</strong> regimens available as proposed by ACOG guidelines - Consider for B-hCG level &gt; 5,000 mIU/mL</li>\n</ul>\n<h2 id=\"references\">References</h2>\n<ul>\n<li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18515537\">ACOG Practice Bulletin No. 94:Medical management of ectopic pregnancy. Obstet Gynecology. 2008; 111(6):1479-85.</a></li>\n</ul>\n"}}